TNFRSF17 and Miyoshi myopathy: In recent years, the chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have achieved encouraging results, which brings hope to the cure of MM (6, 9, 10).